Document Classification

Section Type: RESULTS

Text: At week 12, OM 40/AML 10/HCTZ 25 mg resulted in significantly greater SeBP reductions in participants with diabetes (-37. 9 / 22. 0 mm Hg vs -28. 0 / 17. 6 mm Hg for OM 40/AML 10 mg, -26. 4 / 14. 7 mm Hg for OM 40/HCTZ 25 mg, and -27. 6 / 14. 8 mm Hg for AML 10/HCTZ 25 mg), CKD (-44. 3 / 25. 5 mm Hg vs -39. 5 / 23. 8 mm Hg for OM 40/AML 10 mg, -25. 3 / 17. 0 mm Hg for OM 40/HCTZ 25 mg, and -33. 4 / 20. 6 mm Hg for AML 10/HCTZ 25 mg), and chronic CVD (-37. 8 / 20. 6 mm Hg vs -31. 7 / 18. 2 mm Hg for OM 40/AML 10 mg, -30. 9 / 17. 1 mm Hg for OM 40/HCTZ 25 mg, and -27. 5 / 16. 1 mm Hg for AML 10/HCTZ 25 mg) (P < 0. 05 for all subgroups vs dual-component treatments).